The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research in women’s health uncovered significant findings related to endometriosis and… Read More
News round-up for 12 – 16 January by Bruno Quinney, Content Team at DDW. This week in DDW, new research in women’s health has uncovered significant findings related to endometriosis and ovarian cancer. Elsewhere, can ageing be reversed? The top stories: Discovery reveals endometriosis is not… Read More
A novel DNA-based therapy could increase survival rates for women with platinum-resistant ovarian cancer, a new paper reveals. A new clinical study, published in the International Journal of Gynecological Cancer, shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival… Read More
CureLab Oncology’s DNA vaccine Elenagen, in combination with chemotherapy, has demonstrated promising clinical results against triple-negative ovarian cancer. The study shows that disease progression was significantly delayed in a group of stage III and IV platinum-resistant ovarian cancer (PROC) patients who received gemcitabine in combination with… Read More
A novel DNA vaccine in combination with chemotherapy has demonstrated promising clinical results against a deadly form of ovarian cancer. The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a… Read More
Dr John Ballantyne, co-founder of Aldevron, has invested $3 million in CureLab Oncology and CureLab Veterinary. The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr Ballantyne served there as chief scientific officer. Both CureLab Oncology and CureLab Veterinary are… Read More
